Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > BUSINESS
BUSINESS
- Sanofi-Aventis Files NDA for GLP-1 Receptor Agonist Lixisenatide in Japan
June 13, 2012
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
- DSP to Seek Additional Indication of Bipolar Depression for Latuda in US
June 11, 2012
- University of Tokyo Hospital to Take Over Development of Takeda’s AD Treatment Candidate
June 11, 2012
- Ethical Drug Sales Up 7.0% in April: Crecon Report
June 11, 2012
- 2012 MR Trend Survey
June 11, 2012
- Shionogi Aims to Boost ARB Product Lineup with Launch of Combination Drugs
June 8, 2012
- Astellas to Collect Additional Data Comparing Tivozanib with Sunitinib
June 8, 2012
- Tuberculosis Treatment Delamanid Demonstrates 53% Increase in SCC: Otsuka
June 8, 2012
- Prescriptions by Generic Names Further Spreading, Amlodipine Most Frequently Prescribed: Pharmacist Survey
June 7, 2012
- Astellas Initiates PIIb Dose Finding Study for AC220 in Europe and US
June 7, 2012
- DSP, Shionogi to Comarket Combination Drug of Irbesartan, Amlodipine
June 7, 2012
- Novartis Pharma Revises Package Insert for Hypertension Treatment Rasilez
June 7, 2012
- Mr Mark Swindell Appointed Head of Specialty Care: Pfizer Japan
June 7, 2012
- Teva Pharma’s Committee Compiles Report on Issues at Former Taiyo Pharmaceutical Factory
June 6, 2012
- Astellas to Collaborate with US Company to Develop Bombesin BB2 Receptor Antagonist
June 6, 2012
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…